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Opioid Overdose Deaths in Tennessee
Key Points
● Opioid overdose deaths (ODD) are best understood as three phases: first due to
prescription opioid misuse, followed by a rise in heroin use, and currently due to
contamination by synthetic opioids such as fentanyl. Each phase has posed unique
policy challenges.
● Numerous policies and practices have successfully reduced prescription opioid and
heroin ODD, but ODD due to fentanyl and other synthetic opioids continue to rise,
especially since the COVID-19 pandemic began.
● Fentanyl test strips, syringe service programs, greater naloxone (Narcan, Kloxxado)
availability and other harm reduction approaches have been implemented in recent
years with positive results, but synthetic opioids continue to cause deaths due to their
extreme potency and widespread availability.
● Expanding access to treatment is crucial to reducing ODD. Such policies include
initiating medication for opioid use disorder (MOUD) within jails and emergency
departments, reducing the behavioral health workforce pay gap, and expanding health
insurance access.
● Additional harm reduction and prevention policies may have an even greater impact on
reducing ODD.

Opioid Overdose Deaths (ODD): Three Phases
In the late 1990s, due to misleading and aggressive marketing by Purdue Pharma and
other drug manufacturers that novel opioids such as OxyContin were non-addictive, physicians
across the country began dramatically overprescribing opioids. This caused widespread
prescription opioid misuse among patients, wherein people were improperly sharing
prescriptions. In the early 2010s, over 60% of people with a known history of opioid
prescription misuse reported obtaining their first dose from a friend or family member either
for free or for a price. By 2012, opioids had overtaken alcohol as the primary substance of
dependence among those receiving treatment funded by the Tennessee Department of Mental
Health and Substance Abuse Services, while drug ODD increased 220% from 1999.

Healthcare providers, insurers, and policymakers began reacting to what had then
become an epidemic of opioid misuse. In 2014, Tennessee launched the Prescription to Success
Act, a statewide strategic plan developed by the Tennessee Department of Mental Health and
Substance Abuse Services and other agencies to build on existing efforts to combat the
epidemic. Key elements of this plan included establishing a Good Samaritan law, revising the
Tennessee Intractable Pain Treatment Act and Tennessee Code to reform prescribing guidelines
and better regulation of pain management clinics, restricting direct-to-consumer advertising for
pain medication, implementing new guidelines for acute care and emergency room prescribing,
improving the Tennessee Controlled Substance Monitoring Database (CSMD), and many other
efforts that had a demonstrable and significant impact on the rate of prescription opioid misuse
and ODD.
Unfortunately, as the supply of prescription opioids became more restricted, many
people began turning to illicit sources such as heroin. Even as ODD due to prescription opioids
declined, deaths due to heroin overdose began spiking, especially as synthetic opioids such as
fentanyl, which is up to 100 times stronger than morphine, entered the market. In 2019, three
out of every four heroin ODD involved fentanyl. Fentanyl has quickly become the number one
cause of opioid ODD, and is now involved in over 50% of all drug ODD.

It is important to keep in mind that the majority of all opioid ODD involve multiple
drugs, known as polydrug overdose. This means people are pairing opioids with a
benzodiazepine or a muscle relaxer, further enhancing the depressant effects, or with a
stimulant like methamphetamine or cocaine in order to counteract the opioid’s depressant
effect with the stimulant’s energy boost. Polydrug use is often intentional. Even as deaths due
to fentanyl and other opioids continue to climb, the rate of polydrug overdose has remained
stable since 2015, meaning that the overdose epidemic cannot be viewed as a problem
exclusive to opioids.

The Danger of Fentanyl
Many people unknowingly ingest fentanyl for several reasons. Despite being exponentially
stronger than heroin, fentanyl is about 18.5 times cheaper (heroin costs about $65,000 per
kilogram and fentanyl about $3,500 per kilogram. Because of this, dealers can maximize their
profits by lacing fentanyl into other substances, even mixing it with flour or baking soda.
Dealers also lace fentanyl into other illicit drugs, including methamphetamine. All illicit drugs
carry the risk of fentanyl contamination.
A particularly nefarious product is the fake prescription pill: dealers use illegal pill presses to
manufacture a fentanyl-laced pill that resembles OxyContin or another prescription, such as
counterfeit Xanax. People that buy these pills on the street think they know what drug and
dose they are about to ingest. However, due to the presence of fentanyl, they
unintentionally overdose.
Importantly, some people intentionally seek out fentanyl because their baseline tolerance
has grown so high that synthetic opioids are the only way to feel the euphoric effects that
make the drugs addictive in the first place. Despite their high tolerance, even these
individuals risk death because there is no way to know for sure the potency of any drug
bought on the street.

Responses to a Changing Problem
The first phase of the opioid epidemic was met with policies and programs that had a
strong impact on reducing ODD involving prescriptions, but the heroin and fentanyl phases
introduced new challenges that have been met with new solutions. In 2018, Tennessee
released a multi-faceted plan known as TN Together, which builds on the Prescription to
Success Act. Among prevention strategies such as changing TennCare coverage to limit opioid
prescriptions, $25 million was appointed to treatment programs, including within correctional
facilities.
There have been several harm reduction efforts as well. In addition to expanding access
to the opioid antagonist naloxone and providing civil protection to those who administer it,
Tennessee legalized syringe service programs (SSPs) in 2018. SSPs are significant distributors of

naloxone, and importantly, SSP participants are five times more likely to enter long term
recovery treatment.

The Pandemic Effect
Despite these monumental efforts, the coronavirus pandemic contributed to a dramatic,
unprecedented, and persistent spike in ODD. Between February 2020 and April 2021,
Tennessee saw a 60% increase in ODD. Widening our scope, we see a 101.2% increase in ODD
between January 2019 and January 2022, with an overall quintupling since the start of the
epidemic in 1999. There are more people dying of overdose than ever before in the state’s
history, and it is clear that the pandemic was a significant contributor to this acceleration.
In response to the pandemic, Executive Orders and Special Session legislation increased
telehealth permissions, which significantly expanded access to medications for opioid use
disorder (MOUD), contributing to a marked increase in patients seeking recovery services in
Tennessee. These permissions were made permanent in 2022. Tennessee also passed Public
Chapter 771 and Public Chapter 761 in the summer of 2020, authorizing nurse practitioners and
physician assistants to prescribe the MOUD buprenorphine in various contexts. Early the next
year, the U.S. Department of Health and Human Services removed the requirement for
prescribers to undertake specific training courses in order to gain buprenorphine privileges.

Medications for Opioid Use Disorder
Research shows that medications for opioid use disorder (MOUD) dramatically reduce
the risk of death. However, MOUD still remain underutilized in residential treatment
programs. However, MOUD acceptance is growing due to the significant increase in
treatment retention and completion, overwhelming reduction in mortality, suicidality, and
crime.
Naltrexone is an opioid antagonist, meaning it blocks opioids from binding to
receptors, making it impossible to get high. It does not prevent withdrawal, however.
Methadone is an opioid agonist, meaning it is itself an opioid, but much less potent
than heroin or fentanyl. Its primary purpose is to allow the patient and their provider to
taper down the patient’s daily opioid intake, so that they can control withdrawal symptoms
and enter long term recovery. Additionally, methadone has been strongly associated with a
reduction in illicit drug use such as heroin.
Buprenorphine is a partial opioid agonist, meaning it binds to opioid receptors and
blocks any further opioid doses from having an effect while also preventing withdrawal
symptoms. Additionally, Buprenorphine is less likely to be misused due to these receptor
blockers. Buprenorphine is known to have a mortality benefit of at least 50%, meaning that
more than half of patients taking it would have otherwise died by overdose.

Additionally, the CDC announced in April 2021 that federal funds may be allocated to
Fentanyl Test Strips (FTS), and in March 2022, the Tennessee General Assembly passed Public
Chapter 764, excluding FTS from being considered drug paraphernalia. As the name suggests,
the test strips indicate if there is a presence of fentanyl in any substance tested. Studies have
shown that FTS are effective in reducing risk of OD by changing drug use habits and using safely
through avenues such as SSPs.

Remaining Challenges
While access to treatment has been significantly expanded (especially via telehealth)
and TennCare’s coverage of services has increased, there are still several barriers to access for
many Tennesseans.

Despite changes at the federal and state level to increase the number of providers
capable of prescribing buprenorphine, there were only 1,007 such providers in 2020 in
Tennessee. About half of these had a patient cap of 30, and 26 counties lacked such a provider
altogether. Additionally, it is anticipated that Tennessee’s behavioral health workforce
shortages will worsen. By 2030, Tennessee is expected to have a gap of 780 psychiatrists, 830
substance use counselors, 890 psychologists, and 1,270 mental health counselors. Overall, only
13.2% of Tennessee’s psychiatric needs are being met. A significant contributor to this is a gap
in reimbursement rates. On average, Tennessee pays its behavioral health workforce over 15%
less than the US average. Social workers specializing in mental health and substance use are
particularly impacted, receiving an average of about 21% less pay than their peers in other
states.

May 2020 State Occupational Employment and Wage Estimates

A major cause of the pay gap is the large number of uninsured Tennesseans, which are
overrepresented in the substance use population. Over 11% of Tennesseans - nearly 800,000
people - do not have health insurance of any kind. Even with telehealth permissions and
increased TennCare coverage, treatment can be prohibitively expensive for the population at
greatest risk for fatal overdose. Uninsured patients must pay for services with cash, and as
MOUD treatment can cost almost $5,000 per patient per year, many patients simply cannot
afford services even when they are available. Because opioid use is associated with a significant
decline in workforce participation, and a person’s likelihood of passing a drug screen
dramatically affects employment opportunities, it is clear that the population at greatest need
for public insurance is the population at greatest risk of opioid death: the uninsured.

Knox County Overdose Fatality Review
The Overdose Fatality Review (OFR) is a new interagency task force whose purpose is to “take
a deep dive into the lives of individuals who have fatally overdosed to identify trends and
missed opportunities that occurred during their life.” This involves reviewing medical
records, data from the criminal justice system, toxicology reports and many other sources in
order to build a comprehensive picture of the trends that are associated with fatal overdoses
so that prevention efforts can be better informed and targeted.
Dr. Maranda Williams, the current director of the Knox County OFR, hopes to make the
biggest impact on encounters with emergency departments and incarceration facilities, as
these are major points of contact between people with substance use disorder and potential
access to resources. A notable finding is that overdose deaths typically occur in people that
lack health insurance, and similarly lack legal prescriptions.
The Knox County OFR began in 2021, and there are hopes to launch teams in Davidson,
Rutherford and Hamilton counties as well. While they are having an impact, Dr. Williams
informed SMART that they have been limited in some ways. For example, they are not
allowed to interview families of subjects.

Policy Options
Access: MOUD in Correctional Facilities and Emergency Departments
Due to over 80% of all Tennessee crimes relating to drugs and people with substance
use disorder being overrepresented in the incarcerated population, the criminal justice system
represents an important treatment access point. If a person with an opioid use disorder is
incarcerated, it will not take long before opioid withdrawals begin. Similarly, such a person is at
markedly heightened risk of overdose death upon community re-entry due to a natural
reduction in tolerance. If, however, MOUD treatment is continued or initiated during
incarceration, there is a significant reduction in ODD upon re-entry. Such a program has been
launched in Jefferson County, Tennessee. For more information, please see our policy brief on
continuity of care for incarcerated populations.
Similarly, the predominant model for addiction treatment in the context of emergency
departments (EDs) is known as Screening, Brief Intervention and Referral to Treatment (SBIRT),
wherein the treating provider - more often than not following the reversal of a potentially fatal
overdose - discusses substance use disorder with the patient and gives them a referral list for

nearby programs. While the SBIRT model does have some efficacy, studies show that initiating
MOUD treatment in the ED is even more effective, with an increased chance of patients
utilizing long-term recovery services, decreased drug use, and decreased use of inpatient
services. The American College of Emergency Physicians now recommends that providers
initiate MOUD treatment in the ED.

Harm Reduction: Supervised Injection Sites
By increasing the availability of naloxone and legalizing syringe service programs,
Tennessee has already begun to embrace harm reduction policies in an effort to reduce ODD.
However, fentanyl is so lethal and so available that people are still dying in the “largest
numbers we’ve ever seen,” despite the monumental steps taken thus far. Supervised injection
facilities (SIF), also known as overdose prevention centers, are a type of harm reduction
program not unlike syringe service programs (SSPs). Whereas SSPs provide a place for people
who use drugs to obtain clean hypodermic needles and naloxone, as well as connections to long
term recovery services, SIFs also provide a space for people to inject drugs under the
supervision of a clinician trained in naloxone administration. SIFs have been associated with a
marked decrease in overdose mortality compared to the surrounding areas (35% decrease
versus 9%), a significant reduction in infectious disease transmission (such as HIV) as well as
overall drug use, and increased access to healthcare and social services. In November 2021,
two SIF opened in New York City and averted 59 overdose deaths in the first three weeks of
operation. The first legal SIF in the United States was opened in Rhode Island earlier that year.
Though the Department of Justice prevented the opening of a facility in Philadelphia in 2019,
the DOJ has not interfered with either the Rhode Island or New York facilities.
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